Details:
The company is currently tackling hypometabolism in an ‘orphan’ neurological disease named Glucose Transporter 1-Deficiency Syndrome. This rare disease is characterized by a reduced entry of glucose into the brain that leads to severe symptoms in children and adults.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Wyss Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 24, 2022
Details:
In the new collaboration, companies aim to generate and validate human-derived monoclonal antibodies (NI504) against Ono’s selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resulting from collaboration.
Lead Product(s): Human-derived Monoclonal Antibodies
Therapeutic Area: Neurology Product Name: NI504
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2022